



## **MannKind to Present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference**

12/01/10

MannKind to Present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference

VALENCIA, Calif., Dec 01, 2010 (BUSINESS WIRE) -- **MannKind Corporation (Nasdaq: MNKD)**, focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Canaccord Genuity 5<sup>th</sup> Annual Cardiovascular, Diabetes & Obesity Conference on Wednesday, December 8, 2010 at 10:00 AM (PT) at the Nikko Hotel in San Francisco, CA.

Interested parties can access a link to the live webcast of the presentation from the News & Media section of the Company's website at [www.mannkindcorp.com](http://www.mannkindcorp.com).

### **About MannKind Corporation**

MannKind Corporation (NASDAQ:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA<sup>®</sup> and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted an NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response letter to this NDA from the FDA, requesting additional information. In July 2010, the FDA accepted MannKind's reply to the Complete Response letter and set a PDUFA action date of December 29, 2010. Other products in MannKind's pipeline include the cancer immunotherapy platform MKC1106, which is currently in phase 2 clinical trials. MannKind maintains a website at [www.mannkindcorp.com](http://www.mannkindcorp.com) to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SOURCE: MannKind Corporation

MannKind Corporation  
Matthew J. Pfeffer  
Corporate Vice President and Chief Financial Officer  
661-775-5300  
[mpfeffer@mannkindcorp.com](mailto:mpfeffer@mannkindcorp.com)